Company news
Nasus Pharma Ltd. (AMEX:NSRX) news
Every Nasus Pharma Ltd. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Nasus Pharma Announces Transition of Chief Financial Officer
August 19, 2026
Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update
August 17, 2026
Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growth
July 28, 2026
Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003)
June 9, 2026
Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update
March 25, 2026
Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrin...
March 16, 2026
Nasus Pharma to Present Topline Analysis from NS002 Intranasal Epinephrine Powder Phase 2 Single and Repeat Dose Clinical Study
March 9, 2026
Nasus Pharma to Present and Participate in the Upcoming Life Sciences Investor Forum
March 9, 2026
Nasus Pharma to Participate in Upcoming Investor Conferences
February 20, 2026
Nasus Pharma to Present Data Highlighting Superior Nasal Deposition and Stability of Intranasal Epinephrine Powder at AAAAI 2026
February 17, 2026
Nasus Pharma Announces Closing of $15.0 Million Private Placement
February 13, 2026
Nasus Pharma Announces Pricing of $15.0 Million Private Placement
February 10, 2026
Nasus Pharma Announces Positive Interim Results from Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder
January 20, 2026
Nasus Pharma CEO Issues 2025 Letter to Shareholders
December 22, 2025
Nasus Pharma Strengthens Leadership Team, Appointing Eyal Rubin as Executive Vice President and Chief Financial Officer
November 20, 2025
Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed
November 18, 2025
Nasus Pharma Announces Approval from Health Canada to Initiate Planned Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder
November 6, 2025
Nasus Pharma Announces Expanded Agreement to Support Development and Commercialization of NS002 Intranasal Epinephrine Program
October 8, 2025
Nasus Pharma Announces Upcoming Presentation at H.C. Wainwright 27th Annual Global Investment Conference
September 2, 2025
Nasus Pharma Marks NYSE American Listing with Bell Ringing Ceremony
August 26, 2025
Nasus Pharma Announces Closing of Initial Public Offering
August 14, 2025
Nasus Pharma Announces Pricing of $10 Million Initial Public Offering
August 13, 2025